Eli Lilly and Company (NYSE:LLY) Trading 3.9% Higher – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) shot up 3.9% during trading on Wednesday . The company traded as high as $976.68 and last traded at $955.4470. 6,165,708 shares changed hands during trading, an increase of 91% from the average session volume of 3,220,580 shares. The stock had previously closed at $919.77.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo — a major commercial catalyst that expands the company’s obesity franchise into an oral, scalable offering and intensifies competition with Novo Nordisk. This approval is the primary near‑term bullish trigger. Lilly’s weight-loss pill wins US approval
• Positive Sentiment: Market commentary and options pricing point to further upside after Foundayo’s approval — analysts and options markets are pricing an expectation of higher LLY moves over the next 1–3 months. Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?
• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals (deal up to ~$7.8B), adding sleep‑wake disorder assets and diversifying beyond obesity/diabetes — a strategic M&A move that supports longer‑term revenue growth and reduces single‑product concentration risk. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Unusual call‑option activity: unusually large volume of LLY calls was traded today, consistent with bullish positioning from traders expecting further share gains.
• Positive Sentiment: Lilly’s big AI and R&D investments (multi‑billion partnerships) signal a pipeline acceleration strategy that supports a premium valuation over the medium term. Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?
• Neutral Sentiment: Novo Nordisk’s pricing/subscription moves for Wegovy keep competitive pressure on pricing and market share for obesity drugs — increases industry competition but doesn’t negate Foundayo’s market entry. Novo Nordisk (NVO) Stock: New Wegovy Subscription Pricing Takes on Eli Lilly
• Neutral Sentiment: An investor law‑firm inquiry into the Centessa sale process was filed — watch for procedural noise, but this is a common occurrence in M&A and not yet a material operational threat. Centessa Pharmaceuticals Investor Alert
• Negative Sentiment: Lilly’s CEO publicly opposed codifying the “Most Favored Nations” (MFN) drug pricing deals into law — this stance could attract policy scrutiny and political risk around pricing reforms. Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO says
• Negative Sentiment: Guggenheim lowered near‑term expectations for LLY — an analyst downgrade or reduced estimates can weigh on sentiment even amid positive company news. Guggenheim Has Lowered Expectations for Eli Lilly

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “buy (b)” rating on shares of Eli Lilly and Company in a research note on Friday. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, CICC Research boosted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,221.26.

Eli Lilly and Company Trading Up 3.9%

The business has a 50-day moving average price of $1,001.75 and a 200-day moving average price of $966.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market capitalization of $902.72 billion, a P/E ratio of 41.63, a PEG ratio of 1.03 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same period last year, the business earned $5.32 earnings per share. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently made changes to their positions in the business. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $12,976,634,000. Capital Research Global Investors boosted its stake in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP boosted its stake in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after buying an additional 4,038,502 shares in the last quarter. Cardano Risk Management B.V. grew its position in Eli Lilly and Company by 876.1% in the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after acquiring an additional 2,131,734 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after acquiring an additional 1,432,069 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.